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Abstract
Pharmacogenetic (PGx) testing is increasingly available from clinical laboratories. However, only 
a limited number of quality control and other reference materials (RMs) are currently available to 
support clinical testing. To address this need, the Centers for Disease Control and Prevention 
(CDC) based Genetic Testing Reference Material Coordination Program (GeT-RM), in 
collaboration with members of the pharmacogenetic testing community and the Coriell Cell 
Repositories, has characterized 137 genomic DNA samples for 28 genes commonly genotyped by 
PGx testing assays (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, DPYD, GSTM1, GSTP1, GSTT1, NAT1, NAT2, 
SLC15A2, SLC22A2, SLCO1B1, SLCO2B1, TPMT, UGT1A1, UGT2B7, UGT2B15, UGT2B17, 
VKORC1). 137 Coriell cell lines were selected based on ethnic diversity and partial genotype 
characterization from previous testing. DNA samples were coded and distributed to volunteer 
testing laboratories for targeted genotyping using a number of commercially available and 
laboratory developed tests. Through consensus verification, we confirmed the presence of at least 
108 variant PGx alleles. These samples are also being characterized by other PGx assays, 
including next-generation sequencing, which will be reported separately. Genotyping results were 
consistent among laboratories, with the majority of differences in allele assignments attributed to 
assay design and variability in reported allele nomenclature, particularly for CYP2D6, UGT1A1, 
and VKORC1. These publicly available samples will help assure the accuracy of pharmacogenetic 
testing.
Introduction
Pharmacogenetic tests are used to predict or explain an individual’s reaction to drugs by 
assaying for the presence or absence of known genetic polymorphisms in genes encoding 
drug metabolizing enzymes, drug transporters, drug receptors or targets of drug action. 
These tests are used clinically to assist development of therapeutic strategies. For example, 
clopidogrel (Plavix®) is a platelet inhibitor that is prescribed to patients with acute coronary 
syndromes to prevent blood clots. This drug is metabolized to its active form [2-{1-[1-(2-
chlorophenyl)-2-methoxy-2-oxoethyl]-4-sulfanyl-3-piperidinylidene}acetic acid] by several 
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CYP450 enzymes, most notably CYP2C19. Individuals with loss-of-function CYP2C19 
variants are not able to effectively metabolize clopidogrel and are at increased risk for 
adverse cardiovascular events, especially after receiving coronary artery stents. The boxed 
warning on clopidogrel (http://www.fda.gov/drugs/drugsafety/
postmarketdrugsafetyinformationforpatientsandproviders/ucm203888.htm, last accessed 
9/12/2014) notes that testing is available to determine the CYP2C19 genotype. The FDA 
requires that information about applicable pharmacogenetic tests be included in the labeling 
of certain FDA-approved drugs, including clopidogrel, warfarin and abacavir.1 
Pharmacogenetic tests are also used by researchers and pharmaceutical companies for 
discovery, drug development, and clinical trials.2
Clinical genetic testing laboratories are required by regulations and guided by professional 
or best practice standards to use reference materials (RMs) for assay development and 
validation, quality control and proficiency testing (http://www.acmg.net/Pages/
ACMG_Activities/stds-2002/g.htm, last accessed 4/17/2015, Washington State Legislature, 
http://app.leg.wa.gov/WAC/default.aspx?cite=246-338-090, last accessed 4/17/2015, 
College of American Pathologists http://www.cap.org/apps/cap.portal, last accessed 
4/17/2015 (registration required), New York State Clinical Laboratory Evaluation Program, 
http://www.wadsworth.org/clep, last accessed 4/17/2015).3–9 Genetic testing laboratories 
often use genomic DNA samples, either from cell lines or residual de-identified patient 
material, as RMs. Although clinical laboratories commonly offer pharmacogenetic tests, and 
many pharmacogenetic assays are being used for drug development and clinical trials, there 
are a limited number of quality control and other RMs that have been characterized using 
multiple methods. These materials cover some of the more commonly tested genes and 
alleles included in commercially available reagents and platforms, but no characterized RMs 
are currently available for the majority of genes and alleles included in the more 
comprehensive assays, particularly for low-frequency variants or variants more commonly 
found in non-European populations. This lack of RMs hinders the ability of laboratories to 
develop and validate assays and perform necessary quality control. It also makes comparison 
of assays and standardization between laboratories difficult.
In 2010, the Centers for Disease Control and Prevention (CDC) based Genetic Testing 
Reference Material Coordination (GeT-RM) Program, in collaboration with members of the 
pharmacogenetic testing community and Coriell Cell Repositories, characterized 107 
publicly available genomic DNA samples for five commonly tested PGx genes: CYP2D6, 
CYP2C19, CYP2C9, VKORC1 and UGT1A1.10 This study confirmed the presence of a 
variety of the commonly tested polymorphisms in the five genes; however, many important 
variants were assayed but not identified among the samples tested. An additional study was 
published which characterized 48 samples for CYP2D6 only using multiple methods 
including phenotyping. Two additional CYP2D6 alleles, *43 and *45, that were not tested in 
the GeT-RM study were identified.11
During our first study, clinical laboratories tested only a few pharmacogenetic genes for a 
limited number of variants. Today, a much larger number of pharmacogenetic genes and 
alleles are tested in clinical and research settings. Some commercially available platforms, 
such as the Affymetrix DMET™ Plus Panel or the Agena Bioscience™ iPLEX® ADME 
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PGx Pro Panel and laboratory developed assays that utilize massively parallel sequencing, 
commonly referred to as next generation sequencing (NGS) technology, can examine dozens 
to hundreds of pharmacogenetic genes. In addition, the number of variants that are 
associated with pharmacogenetic phenotypes has increased and knowledge about the effects 
of these variants on drug metabolism is actively being curated, leading to the development 
of practice guidelines for several gene/drug pairs (pharmGKB, Dosing Guidelines- CPIC: 
http://www.pharmgkb.org/view/dosing-guidelines.do?source=CPIC#, last accessed February 
12, 2015).12
To address the increasing need for characterized genomic DNA RMs for pharmacogenetic 
testing of additional PGx genes and alleles, the GeT-RM Program and the genetic testing 
community collaborated to characterize an additional 137 publicly available genomic DNA 
samples for 230 pharmacogenetic genes. The 9 participating pharmacogenetic testing 
laboratories used a variety of commercially available platforms and laboratory developed 
tests, including DNA sequencing assays, to genotype the samples. The findings from this 
study will be reported in two parts. The haplotype analysis of 28 pharmacogenetic genes 
(CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, 
CYP3A4, CYP3A5, CYP4F2, DPYD, GSTM1, GSTP1, GSTT1, NAT1, NAT2, SLC15A2, 
SLC22A2, SLCO1B1, SLCO2B1, TPMT, UGT1A1, UGT2B7, UGT2B15, UGT2B17, 
VKORC1) are reported here, while the results of the DNA sequence analyses and genotyping 
studies will be reported separately.
Materials and Methods
Cell line and laboratory selection
One hundred and thirty-seven cell lines were selected from the National Institute of General 
Medical Sciences (NIGMS) and the National Human Genome Research Institute (NHGRI) 
Repositories at the Coriell Cell Repositories for this study based on data from previous 
partial genotype analysis and the varied ethnicities of the donors. For logistical reasons 
(related to cost of reagents, staffing, and batched run size), the 137 DNA samples were 
divided into two non-overlapping sets: Tier 1 (96 DNA samples) and Tier 2 (41 DNA 
samples). Volunteer laboratories were selected based on assay, platform and willingness to 
participate. Clinical and research laboratories as well as commercial assay manufacturing 
laboratories participated in the study. DNA samples were prepared by Coriell and aliquots 
were sent to the volunteer laboratories for genotyping. Participants utilized a variety of 
commercially available tests, both FDA-cleared and non-FDA cleared, as well as laboratory 
developed tests (LDTs). The alleles detected by each assay, and the sample sets (Tier 1 and 
2) tested by each assay are shown in Table 1. Reagents for the GenMark, Luminex, and 
Affymetrix assays were donated to the testing laboratories by the manufacturers.
DNA preparation—Approximately 2 mg of DNA was prepared from each of the selected 
cell lines by the Coriell Cell Repositories using Gentra/Qiagen Autopure (Valencia, CA) per 
manufacturer’s instructions or previously described methods.13
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Assays used in the characterization study
Affymetrix DMET™ Plus Array (Affymetrix, Santa Clara, CA): Following 
manufacturer’s instructions, genomic DNA was amplified using multiplex PCR and further 
enriched using molecular inversion probe (MIP) PCR. Amplified DNA products were 
purified, fragmented, labeled and hybridized to the DMET™ Plus Array. Arrays were 
stained with a fluorescent antibody and scanned on GeneChip Scanner 3000 7G. Data was 
analyzed using the DMET™ Console Software v. 1.3. The DMET array is optimized to 
detect nucleotide variants and homozygous deletions, and does not distinguish between one 
or more copies of a gene. For CYP2D6, a gene with copy number changes associated with 
clinically relevant phenotypes, three additional Applied Biosystems TaqMan® Gene Copy 
Number Assays (Foster City, CA) were used to test for deletions and duplications. The 
samples were tested according to manufacturer’s instructions and run on the ABI 7900HT 
Real Time PCR System. The copy number data was analyzed using the Applied Biosystems 
TaqMan® Gene Copy Number Assays Macro (http://www3.appliedbiosystems.com/cms/
groups/mcb_marketing/documents/generaldocuments/cms_042731.pdf) and was combined 
with the raw DMET array results to report more conclusive result for CYP2D6.
AutoGenomics INFINITI® CYP3A4-3A5, NAT2, and CYP2D6 Assays (AutoGenomics, 
Inc., Vista, CA): The assays were performed as previously described14 for CYP2C19 using 
multiplex PCR involving target-specific amplification of extracted DNA. Analyte-specific 
detection primer extension and subsequent hybridization of fluorescent labeled primers to 
capture probes arrayed on the Biofilmchip is automated using the INFINITI® analyzer 
which then scans the Microarray, analyzes the data and produces a report indicating 
detection of single nucleotide polymorphisms, copy number variants (deletions, 
duplications), insertions, and other types of variants.
GenMark Dx eSensor® 2C19 Test, Warfarin Sensitivity Test, and 3A4/3A5 Assays 
(GenMark Diagnostics, Carlsbad, CA, USA): All genotyping was performed as per the 
manufacturer’s instructions. The technology and performance of GenMark genotyping has 
been described elsewhere.15–17 In brief, the regions surrounding the interrogated variants 
were amplified using multiplex PCR, incubated with allele-specific oligonucleotide signal 
probes labeled with a ferrocene derivative, and hybridized with capture probes bound to 
gold-plated electrodes through test-specific eSensor® cartridges and the eSensor® XT-8 
System (GenMark Diagnostics). All genotypes were determined by voltammetry using the 
eSensor® analysis software (GenMark Diagnostics, Carlsbad, CA, USA).
iPLEX® ADME PGx Pro Panel (Agena Bioscience, San Diego, CA): Specific DNA 
fragments were amplified from genomic DNA in eight PCR reactions and alleles were 
subsequently interrogated using single base extension (SBE) reactions. Genotypes were 
detected using a MassARRAY® Analyzer 4 system and haplotypes assigned using an 
ADME PGx Pro Reporter plugin for the Typer Analyzer software (Agena Bioscience, San 
Diego, CA). The UGT1A1 TA repeat assay genotypes were also incorporated into the 
ADME PGx Reporter output using a modified ADME PGx Pro database (http://
www.biotechniques.com/protocols/2012_Protocol_Guide/Development-and-Research-
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Validation-of-the-iPLEX----ADME-PGx-Panel-on-the-MassARRAY-System/
biotechniques-330915.html, last accessed April 17, 2015).
iPLEX® ADME CYP2D6 Panel (Agena Bioscience, San Diego, CA): Specific DNA 
fragments were amplified from genomic DNA in three PCR reactions and alleles were 
subsequently amplified using SBE. Genotypes were detected using a MassARRAY® 
Analyzer 4 system and haplotypes assigned using an ADME CYP2D6 Reporter plugin for 
the Typer Analyzer software (Agena Bioscience, San Diego, CA).
iPLEX® ADME CYP2C9/VKORC1 Panel (Agena Bioscience, San Diego, CA): Specific 
DNA fragments were amplified using genomic DNA in three PCR reactions and 
subsequently alleles were interrogated using SBE. Genotypes were detected using a 
MassARRAY® Analyzer 4 system and haplotypes assigned using an ADME CYP2C9/
VKORC1 Reporter plugin for the Typer Analyzer software (Agena Bioscience, San Diego, 
CA).
iPLEX® ADME CYP2C19 Panel (Agena Bioscience, San Diego, CA): Specific DNA 
fragments were amplified using genomic DNA in two PCR reactions and subsequently 
alleles were interrogated using SBE. Genotypes were detected using a MassARRAY® 
Analyzer 4 system and haplotypes assigned using an ADME PGx Pro Reporter plugin for 
the Typer Analyzer software (Agena Bioscience, San Diego, CA)
iPLEX® UGT1A1 TA Repeat Assay (Agena Bioscience, San Diego, CA): A specific DNA 
fragment was generated using PCR and genomic DNA and alleles were subsequently 
interrogated using a homogeneous mass extension reaction. Genotypes were detected using 
a MassARRAY® Analyzer 4 system and assigned manually using the Typer Analyzer 
software (Agena Bioscience, San Diego, CA). The TA repeat genotypes were also 
incorporated into the ADME PGx Reporter output using a modified ADME PGx Pro 
database.
Laboratory developed test for LifeTech Taqman® Platform: Specimens were analyzed 
using the LifeTech QuantStudio 12K Flex (software v1.2.2; Grand Island, NY) and 
subjected to Taqman® allele discrimination using LifeTech (Grand Island, NY) reagents in 
a custom-designed open array. Genomic DNA was amplified and mixed with dual-labeled 
oligonucleotides that hybridize to a specific target sequence. Hydrolysis by the 5′-3′ 
exonuclease activity of Taq polymerase releases the fluorescent reporter signal, permitting 
quantitative measurement of the accumulation of the PCR product via the fluorophore 
signal.18 Software utilized were Genotyper (v1.3) (LifeTech, Grand Island, NY) and 
Alleletyper (1.0) (LifeTech, Grand Island, NY).
For copy number analysis, CYP2D6 and a reference gene were compared using 
commercially available reagents from LifeTech (Grand Island, NY). Individual samples 
were run in quadruplicate. Each replicate was normalized to the reference gene to obtain a 
ΔCt (FAM dye Ct, VIC dye Ct), and then an average ΔCt for each sample (from the 4 
replicates) was calculated. All samples were then normalized to a calibrator sample to 
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determine ΔΔCt. Relative quantity (RQ) is 2-ΔΔCt, and copy number is 2 X RQ. Copy 
number was assigned using CopyCaller®Software (v 2.0) (LifeTech, Grand Island, NY).
Luminex xTAG® CYP2C19 Kit v3, CYP2C9+VKORC1 Kit, CYP2D6 Kit v3 (Luminex 
Molecular Diagnostics, Toronto, ON, Canada): All genotyping was performed as per the 
manufacturer’s instructions. The technology and performance of Luminex genotyping has 
been described elsewhere.17, 19, 20 Briefly, the regions surrounding the interrogated variants 
were multiplex PCR-amplified, subjected to allele-specific primer extension, hybridized to 
specific xMAP microspheres via oligonucleotide tags, and fluorescence measured on a 
Luminex xMAP platform (Luminex Corporation, Austin, TX, USA). All genotypes were 
determined using the appropriate xTAG® Data Analysis Software (Luminex Molecular 
Diagnostics).
Characterization Protocol—Each of the testing laboratories received one 10-μg aliquot 
of DNA from each of the cell lines to be tested. The samples were coded and the expected 
genotypes were not revealed to the laboratories. Each laboratory tested Tier 1 samples or 
both Tier 1 and Tier 2 samples using their standard assay methods. The platforms and assays 
used in the study, the alleles detected by each, and the sample set(s) tested with each method 
are indicated in Table 1. The results were submitted to the study coordinators (LVK, VMP, 
and REE), who examined the data for quality and discrepancies, and determined the 
consensus genotype. If discrepancies were noted, the participating laboratory was requested 
to re-evaluate the sample in question (without providing the expected genotype) to 
determine the cause of the inconsistency.
Results
Unless otherwise stated, the “wild-type” (*1) alleles were assigned in the absence of other 
detectable variant alleles.
DNA samples from Coriell cell lines containing pharmacogenetic variants that are 
frequently included in expanded panel pharmacogenetic assays were selected for this study. 
A list of 221 variants in 41 genes that were included in two or more commonly used and 
comprehensive pharmacogenetic assays [Affymetrix DMET, Agena Bioscience™ (formerly 
Sequenom) iPLEX® ADME PGx Pro, Illumina VeraCode ADME, and some laboratory 
developed tests] was assembled. Sources of data, including the Coriell Repository catalog 
(http://www.coriell.org/research-services/cell-culture/biobank-catalog last accessed April 
20, 2015), the 1000 Genomes Project (http://www.ncbi.nlm.nih.gov/variation/tools/
1000genomes/ last accessed March 3, 2015), and genotypic data from collaborating 
laboratories were examined to identify Coriell cell lines expected to have variants in the 
targeted alleles. Based on this analysis, DNA from 137 cell lines from the Coriell 
Repositories were selected for further characterization and consensus verification.
Nine laboratories, using a variety of pharmacogenetic assays, volunteered to test the 
samples. The results from five laboratories (5 platforms, 7 assays Table 1) that reported 
diplotype data are described here. The results of the DNA sequence analysis and other 
genotyping assays will be presented separately. Consensus diplotypes were determined by 
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examining the variant calls made by each platform. There was good concordance among the 
platforms; however, discrepancies in diplotype assignments related to assay design and 
variable nomenclature were identified. Discrepancies in diplotype calls between platforms 
were resolved by manually evaluating the stated haplotypes in light of the variants tested by 
each platform. Available databases such as The Human Cytochrome P450 (CYP) Allele 
Nomenclature Database (www.cypalleles.ki.se, last accessed March 3, 2015) and 
PharmGKB (www.pharmgkb.org, last accessed March 3, 2015) were used as haplotype 
standards for the various genes (Web resources - Supplemental Table 1). The consensus 
diplotype data for 28 genes that were tested using two to six platforms (CYP1A1, CYP1A2, 
CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, 
CYP4F2, DPYD, GSTM1, GSTP1, GSTT1, NAT1, NAT2, SLC15A2, SLC22A2, SLCO1B1, 
SLCO2B1, TPMT, UGT1A1, UGT2B7, UGT2B15, UGT2B17, and VKORC1) are shown in 
the Consensus Table – Supplemental Table 2. Diplotype calls from all platforms used to 
make the consensus calls on the 28 genes are available on the GeT-RM website (http://
wwwn.cdc.gov/clia/Resources/GetRM/default.aspx last accessed March 3, 2015).
The alleles that were interrogated for each locus, as well as those identified or absent from 
the study samples are listed in Table 2. The alleles detected by each assay platform varied, 
but most common pharmacogenetic variants were identified among the 137 DNA samples. 
Many alleles were included in only one assay due to differences in platform design. Some of 
these were identified in study samples (Table 2), and are presented in the consensus 
diplotype data (Supplemental – Table 2) in parentheses to indicate that this allele has not 
been confirmed by a separate method. Overall, of the 485 unique alleles tested, we identified 
108 alleles by two or more assays and an additional 73 alleles by only one assay.
CYP1A1
Two platforms tested the Tier 1 and one tested the Tier 2 samples for variants in CYP1A1. 
Both platforms were 100% concordant in their genotype calls. Of note, one platform 
identified all *2 variants as *2C. Per The Human Cytochrome P450 (CYP) Allele 
Nomenclature Database, *2A is defined by c.3798T>C (formerly known as m1), *2B is 
defined as having c.3798T>C and c.2454A>G (p.I462V), and *2C is defined as having c.
2454A>G (p.I462V). When *2 or *2C was reported, the consensus was called *2.
CYP1A2
Two platforms tested the Tier 1 and one tested the Tier 2 samples for variants in CYP1A2. 
Both laboratories were 100% concordant in their genotype calls. Of note, neither laboratory 
could distinguish *1A/*1L from *1C/*1F. Per The Human Cytochrome P450 (CYP) Allele 
Nomenclature Database, *1A is defined as no variant detected, *1L is defined as having 
c.-3860G>A and c.-163C>A, *1C is defined as c.-3860G>A and *1F is defined as having 
c.-163C>A.
CYP2A6
Two platforms tested the Tier 1 and one tested the Tier 2 samples for variants in CYP2A6. 
There was relatively good consensus between the platforms, with differences observed 
attributable to the assay design. The Affymetrix platform was optimized for single 
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nucleotide variants and homozygous deletions, but it was unable to identify if only one copy 
of the CYP2A6 deletion (*4 heterozygotes) is present. The Agena Bioscience™ iPLEX 
ADME PGx Pro Panel could detect *8 (g.1454G>T; p.R485L), however, although included 
in the assay, this variant was not detected by the Affymetrix platform. c.-48T>G, which is 
present in *9, *13, and *15, was included in the Agena Bioscience™ iPLEX ADME PGx 
Pro Panel and was reported by this assay as “*9; *13; *15”. The Affymetrix platform detects 
c.-1013A>G for *9. When both c.-48T>G and c.-1013A>G were detected, the consensus 
genotype was called *9 (c.-48T>G, c.-1013A>G).
CYP2B6
Three platforms tested the Tier 1 samples for variants in CYP2B6 and two platforms tested 
the Tier 2 samples. There was relatively good consensus between platforms with most 
differences due to platform design. Only one platform was designed to detect *4, *5, *11, 
*15, *20, *22, and *27 and thus these alleles could not be independently verified. One of the 
challenges in analyzing haplotypes in CYP2B6 is that c.785A>G (p.K262R) is found in 
many alleles, e.g., *4, *6, *7, *14, *16, *20, *26. c.1459C>T (p.R487C) is found in both *5 
and *7. c.516G>T is found in *6, *7, *9, *13, *19, *20, *26, *29, *34, *36, *37, and *38. 
When c.516G>T, c.785A>G, and c.1459C>T are present together, the most likely 
interpretation is *1/*7 with all the variants in cis, though *5/*6 in trans cannot be ruled out 
(see samples NA12717, NA17235, NA17658, NA20509, NA23313, NA23348).
CYP2C8
Three platforms tested the Tier 1 samples for variants in CYP2C8 and two platforms tested 
the Tier 2 samples. The platforms were 100% concordant in their genotype calls. Of note, 
one platform identified all *1 variants as *1A. The other two platforms reported their results 
as *1 when no variant was detected. When *1 or *1A was reported, the consensus was 
called *1.
CYP2C9
Five platforms (6 assays) were used to test the Tier 1 samples for variants in CYP2C9 and 
two platforms (3 assays) were used for the Tier 2 samples. There was relatively good 
consensus between laboratories with most differences due to assay design. Of note, some 
platforms differentiate between *3 and *18. *3 is defined as c.1075A>C (p.I359L) while 
*18 is defined as c.1075A>C (p.I359L) and c.1190A>C (p.D397A). Only one laboratory 
typed the samples for the c.1190A>C variant. While the consensus from the other 
laboratories was *3, the most likely genotype is *18. This affected 11 samples (NA10855, 
NA11839, NA12813, NA17204, NA17234, NA17290, NA17642, NA18563, NA18959, 
NA19917, and NA23405). One platform identified NA19226 and NA18873 as homozygous 
for *8, and two other platforms reported the samples as *1/*8. This may be due to an 
interfering variant in the samples. Additional variants were also identified by only one 
platform in several samples (NA15245, NA19917, and NA23275) which were not defined in 
The Human Cytochrome P450 (CYP) Allele Nomenclature Database.
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CYP2C19
Five platforms (6 assays) were used to test the Tier 1 samples for variants in CYP2C19 and 
two platforms (3 assays) were used for the Tier 2 samples. We identified a problem with one 
of the assays used during this study. Because of the way the assay was designed, *2 and *10 
can be interfering variants and can lead to genotyping errors.21 CYP2C19 *2 is defined by c.
681G>A, and *10 is defined by c.680C>T (p.P227L). This does not affect the phenotypic 
prediction for a patient, but there could be other implications (e.g., proficiency testing). The 
laboratory is working with the platform manufacturer to resolve this issue. Discrepant results 
were found in three samples, (NA19789, NA19908, and NA23275). One platform reported a 
*9 [c.431G>A (p.R144H)] and other platforms designed to detect a *9 failed to detect it. 
The presence of *9 in NA23275 was confirmed by repeat testing with the same assay. In the 
case of NA19789, it is possible that the *9 probe failed. The platform reports these as a 
possible false positive. One sample in the study (NA23878) was found to have the CYP2C19 
*4B (c.1A>G and g.-806C>T) allele.22 Although g.-806C>T is the defining variant for *17, 
two platforms correctly reported the sample as *1/*4B. Of note, we had a number of 
samples (NA07029, NA10865, NA12753, NA18484, NA18524, NA18855, NA19122, 
NA19178, NA23348, NA23872, and NA23873) where variants (identified by only one 
platform) are not defined in The Human Cytochrome P450 (CYP) Allele Nomenclature 
Database.
CYP2D6
Five platforms (6 assays) were used to test the Tier 1 samples for variants in CYP2D6 and 
two platforms (3 assays) were used for the Tier 2 samples. The CYP2D6 *36 allele is a gene 
conversion from CYP2D6 to CYP2D7 in exon 9. Detection of this allele was problematic for 
several platforms in the study because most are not designed to detect *36 and it was 
reported as *10 (NA18524, NA18526, NA18563, NA18564, NA18565, NA18572, 
NA18617, NA18959, NA18980, NA23090, and NA23093). *36 is a gene conversion to 
CYP2D7 in exon 9, or hybrid that, in addition to the gene conversion, contains c.100C>T 
(p.P34S) and c.4180G>C (p.S486T), while CYP2D6*10 contains only c.100C>T (p.P34S) 
and c.4180G>C (p.S486T). *10 is a decreased functional allele while *36 is a non-functional 
allele. One laboratory reported one of the gene conversion samples, NA18565, as having the 
*5 deletion allele. The mostly likely genotype for NA18565 is *10/*36, though the 
consensus is *10/*10. It is suspected that the gene conversion interferes with the primer 
binding sites for the copy number determination as only one copy was detected. 
CYP2D6*35 is defined by c.31G>A (p.V11M), but also contains c.2850C>T (p.R296C) and 
c.4180G>C (p.S486T) that are the defining variants in *2. Platforms not designed to directly 
detect *35, report samples containing all 3 variants as *2 (ie, NA06993, NA07000, 
NA07029, NA12003, NA17204, NA17641, NA17702, and NA20509). Both *2 and *35 are 
normal function alleles, thus the predicted phenotype would not be affected. Sample 
NA19174 was problematic for several platforms and no consensus was determined. One 
platform identified NA19174 as *4/*17 (c.2850C>T, c.1846G>A, c.100C>T, c.1023C>T). 
A second platform did not identify the c.1023C>T and reported NA19174 as *4/*30, a third 
platform identified an unspecified genotype [c.2850C>T, c.4180G>C (homozygous), c.
1846G>A, c.100C>T, c.1023C>T (homozygous)]. Based on the platform designs and 
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variants detected, the most probable allele call for NA19174 is *4/*40 (c.100C>T, c.
1846G>A, c.4180G>C/c.1023C>T, c.1661G>C, c.1863_1864insTTTCGCCCCx2, c.
2850C>T, c.4180G>C). This was also observed in samples NA17102, NA19917, and 
NA23275. Duplications and deletions were also problematic, especially in platforms that 
primarily detect SNPs or insertion/deletions (indels). This affected analysis of samples 
NA10856, NA12336, NA15245, NA18873, NA18945, NA19035, NA19785, NA21781, 
NA23296, NA23297, NA23313, and NA24027. Sample NA24217 was identified by one 
platform as *41/*41X3. The other laboratories reported the genotype as *2/*41XN. 
NA24217 appeared homozygous and not heterozygous for *41, suggesting that there are 
three copies of *41 (i.e., *41XN). We could not determine a consensus CYP2D6 genotype 
for sample NA23878. One platform identified *4/*83 (c.100C>T, c.1846G>A, c. 
4180G>C/c.843T>G, gene conversion to CYP2D7 in exon 9, c.4180G>C), one had an 
unspecified haplotype [c.4180G>C (homozygous), c.1846G>A, 100C>T, 2 copies)], and a 
third platform identified *1/*4 (c.100C>T, c.1846G>A, c. 4180G>C). The most probably 
genotype for this sample is *4/*83. Two platforms identified the *17 variant in sample 
NA19238 and one platform failed to identify it and reported a false negative. Of note, 
additional variants were identified by one platform in two samples (NA19174, NA23878) 
that were not defined in the CYP database.
CYP2E1
Two platforms were used to test the Tier 1 samples and one was used to test the Tier 2 
samples for variants in CYP2E1. There was relatively good consensus between both 
laboratories. The observed discrepancies were due to differences in assay design. The Agena 
Bioscience™ iPLEX ADME PGx Pro Panel was designed to detect and *7, whereas the 
Affymetrix platform detected several other variations not included in the Agena assay, such 
as *4 and *5.
CYP3A4
Five platforms (5 assays) were used to test the Tier 1 samples for variants in CYP3A4 and 
two platforms were used for the Tier 2 samples. There was good consensus between 
platforms. Only one platform was designed to detect *14, *15 and *16 (samples NA15245, 
NA18966, NA19109, NA19226, and NA19908), thus we were not able to independently 
confirm the presence of these variants. They are indicated in parentheses in the consensus 
genotypes.
CYP3A5
Five platforms were used to test the Tier 1 samples for variants in CYP3A5 and two 
platforms were used for the Tier 2 samples. There was good consensus between platforms 
for all samples.
CYP4F2
Two platforms were used to test the Tier 1 samples for variants in CYP4F2, and one 
platform was used for the Tier 2 samples. There are only 2 CYP4F2 alleles, *2 [c.34T>G (p.
12G)] and *3 [c.1297G>A (p.V433M)] detected in the study samples. One platform tested 
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for both alleles and the other platform tested only for the *3 haplotype. When the *2 was 
observed, no consensus was called because it could not be independently confirmed.
DPYD
Three platforms were used to test the Tier 1 samples for variants in DPYD and two 
platforms were used for the Tier 2 samples. Only one platform tested for DPYD *4 [c.
1601C>T (p.S534N)], so the presence of this allele could not be independently confirmed 
for Tier 1 samples NA06991, NA12813, NA12878, and NA24217.
GSTM1, GSTP1, and SLC15A2
Two platforms were used to test the Tier 1 samples for variants in GSTM1, GSTP1, and 
SLC15A2, respectively. There was good consensus between both platforms. One platform 
was used to test the Tier 2 samples.
GSTT1
Two platforms were used to test the Tier 1 samples for variants in GSTT1, and one was used 
to test the Tier 2 samples. There was good consensus between both tests. The Affymetrix 
platform was only able to test for the presence or absence of the gene whereas the Agena 
Bioscience™ iPLEX ADME PGx Pro panel was able to detect whether 0, 1, 2, or more than 
2 copies were present.
NAT1
Two platforms were used to test the Tier 1 samples for variants in NAT1, and one was used 
to test the Tier 2 samples. There was good consensus between both platforms. A consensus 
genotype could not be determined for one sample (NA17204) because of assay failure in one 
laboratory.
NAT2
Two platforms were used to test the Tier 1 samples for variants in NAT2, and one was used 
to test the Tier 2 samples. There was good consensus between both platforms. The major 
difference in haplotypes was related to the alleles that each platform was designed to detect. 
Both platforms agreed very well on the *4, *5, *6 and *7 haplotype calls. Interestingly, 
although both platforms were designed to detect *12 and *14, only the Agena Bioscience™ 
ADME PGx Panel observed the *12 haplotype.
SLC22A2
Two platforms were used to test the Tier 1 samples for variants in SLC22A2, and one was 
used to test the Tier 2 samples. Due to limited annotation for this gene, we were unable to 
easily compare haplotypes. Alleles that were assayed by both platforms revealed identical 
outcomes. Nomenclature issues affected the interpretation and reporting of the results. The 
Agena Bioscience™ platform describes the detected mutations as amino acid changes 
whereas the Affymetrix platform reports star (*) alleles. The nomenclature of this gene is 
not annotated on PharmGKB.
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SLCO1B1
Three platforms were used to test the Tier 1 samples for variants in SLCO1B1 and two 
platforms were used for the Tier 2 samples. The SLCO1B1 *14 haplotype is composed of 
two variants (c.463C>A, c.388A>G) in cis (ie, NA07019, NA07055, NA07056, NA07439, 
NA10831, NA10851, NA12236, NA17244, NA18861, and NA23874). Although it is 
possible that these variants could be in trans (i.e., *1B/*4). A similar issue is observed for 
*15 (c.388A>G, c.521T>C) where the most likely interpretation is that the variants are in cis 
but trans cannot be ruled out (ie, *1B/*5). This affects samples HG00276, NA06993, 
NA07000, NA07357, NA10859, NA12003, NA12892, NA15245, NA17642, NA18526, 
NA19109, NA20509, NA24008, and NA24217. For samples NA18540 and NA18544, the 
most likely interpretation for g.-11187G>A heterozygous, c.388A>G homozygous, c.
521T>C heterozygous is *1B/*17 (c.388A>G,/c.521T>C, g.-11187G>A, c.388A>G), 
though *15/*21 (c.388A>G, c.521T>C/g.-11187G>A, c.388A>G, c.597C>T) cannot be 
ruled out when c.597C>T is not tested. Only one platform, Affymetrix, tested for 
SLCO1B1*21 (g.-11187G>A, c.388A>G, c.521T>C). The other two platforms tested for a 
combination of the variants (g.-11187G>A, c.388A>G, c.521T>C), but not in a single 
platform. In some samples (NA11993, NA12006, NA12156, NA12813, NA17448, 
NA18524, NA18540, NA18544, NA18563, NA18992, and NA23246), g.-11187G>A 
(reported as *21) was detected by the LifeTech platform and *14 was detected by the Agena 
Bioscience™ platform. The most likely interpretation of this genotype is *21, as reported by 
Affymetrix and LifeTech platforms.
SLCO2B1
Two platforms were used to test the Tier 1 samples for variants in SLCO2B1 and one was 
used to test the Tier 2 samples. We could not easily compare haplotypes called by the two 
assays due to differences in nomenclature (results reported as either * nomenclature or 
amino acid change) and limited annotation for this gene. Variants that were assayed by both 
platforms revealed identical outcomes.
TPMT
Three platforms were used to test the Tier 1 samples for variants in TPMT and two platforms 
were used for the Tier 2 samples. There was good consensus between platforms. When c.
460G>A and c.719A>G are present together, the mostly likely interpretation is that they are 
in cis and reported as *3A. Note, it could also be reported as *3B (c.460G>A)/*3C (c.
719A>G) if the two variants are in trans.
UGT1A1
Two platforms (4 assays) were used to test the Tier 1 samples for variants in UGT1A1. 
There was good consensus between both laboratories. The major difference was that the 
Agena Bioscience™ UGT1A1 TA repeat assay could distinguish 5, 6, 7, and 8 TA repeats 
and therefore could distinguish *28 (TA7), *36 (TA5) and *37 (TA8) from *1 (TA6). Data 
from each platform that was used to create the consensus genotype is shown in the UGT1A1 
data table which is available on the Get-RM website.
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UGT2B7
Two platforms tested the Tier 1 samples for variants in UGT2B7 and one platform was used 
to test the Tier 2 samples. There was good consensus between both assays. Since only one 
platform tested for *3 (c.211G>T), the presence of this allele could not be confirmed for 
Tier 1 samples NA18952, NA18973, NA18980, NA18992, and NA19007.
UGT2B15
Two platforms tested the Tier 1 samples for variants in UGT2B15 and one platform was 
used to test the Tier 2 samples. There was good consensus between both assays. Since only 
one platform tested for *4 [c.1568A>C (p.K523T)], the presence of this allele could not be 
confirmed when identified.
UGT2B17
Two platforms tested the Tier 1 samples for variants in UGT2B17 and one platform was 
used to test the Tier 2 samples. The Affymetrix platform is optimized to detect nucleotide 
variants and homozygous deletions, and does not distinguish between one or more copies of 
a gene. The Agena Bioscience™ platform detects only copy number. Therefore, both 
platforms presented identical data for the samples with a homozygous deletion.
VKORC1
Five platforms (6 assays) were used to test the Tier 1 samples for variants in VKORC1 and 
two platforms (3 assays) were used for the Tier 2 samples. There was relatively good 
consensus between laboratories with most differences due to platform design. Most 
laboratories reported only c.-1639G>A genotype. Some laboratories reported using the star 
(*) allele nomenclature and some laboratories reported using the two different haplotype 
nomenclatures. The c.-1639G>A genotype is the defining variant in *2 and is present in 
haplotypes H1, H2 and H5. We reported the consensus genotype only for c.-1639G>A in the 
consensus genotype table (Supplemental Table 2). Data from each platform that was used to 
create the consensus genotype is shown using the H, and star nomenclatures in the VKORC1 
data table which is available on the Get-RM website.
Other Loci
Consensus genotypes could not be determined for 26 additional pharmacogenetic loci that 
were only characterized by one laboratory (ABCC2, ABCC4, CDA, CYP1B1, CYP2A13, 
CYP2F1, CYP2J2, CYP2S1, CYP3A7, CYP3A43, CYP4B1, CYP19A1, FMO2, G6PD, 
IFNL3, ITPA, PTGIS, SULT1A1, TBXAS1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, 
UGT1A8, UGT1A9, and UGT1A10). These data are presented in Supplemental Table 3, and 
on the GeT-RM website.
Discussion
This study describes the characterization of 137 publicly available cell-line derived genomic 
DNA samples for 28 loci potentially included in clinical pharmacogenetic testing. To ensure 
that the DNAs would be thoroughly characterized and would be commutable among a 
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variety of assay chemistries and platforms, each sample was tested using several 
pharmacogenetic assays. We identified many, but not all of the alleles commonly included 
in clinical pharmacogenetic assays for these genes. Additionally, we identified many alleles 
that we did not detect during our previous GeT-RM pharmacogenetics study.10 Some of 
these alleles, including CYP2D6 *10XN, *7, *15, and *41XN and CYP2C19 *6 and *9, 
were found in cell lines created at Coriell from patients known to have pharmacogenetic 
genotypes not identified during the first study. The GeT-RM program will continue 
collaboration with the pharmacogenetic testing community and the Coriell Cell Repositories 
to create and identify cell lines with alleles not identified during this study and undertake 
necessary characterization studies. We also generated haplotype data for an additional 26 
pharmacogenetic loci, which will be corroborated by the results of the DNA sequencing 
analysis in the forthcoming publication. These publicly available DNA samples and 
associated data will be useful for laboratories when developing and validating new genetic 
tests and will also enable proficiency testing programs to provide diverse pharmacogenetic 
challenges.24 Use of reference materials with a variety of alleles can help laboratories to 
characterize and refine their assays, and also may enhance their ability to detect 
pharmacogenetic variants and improve performance on proficiency testing challenges.24
There are a considerable number of polymorphisms in many of the human genes associated 
with pharmacokinetics or pharmacodynamics of exogenous drugs. Sometimes a single 
variant, but often combinations of polymorphisms as a haplotype dictates the activity of the 
pharmacogenetic gene product. Haplotypes usually have one or a few defining variants, but 
may also have additional variants that can be included. Many nomenclature systems have 
been developed to describe pharmacogenetic haplotypes. In the most commonly used 
nomenclature system, combinations of pharmacogenetic sequence variants are designated by 
star (*) alleles, where *1 is designated as normal (commonly referred to as wild-type or fully 
functional) and numbered star alleles are assigned as new variants are identified.23 The star 
nomenclature system is used for many pharmacogenetic genes and gene families, including 
the cytochrome P450 (CYP) gene family. Several nomenclatures, including the star system, 
are intermittently used to describe the haplotypes of other genes, such as VKORC1 and 
UGT1A1. Laboratories in our study often reported allele genotypes for the same gene using 
a variety of nomenclature formats. In many cases, such as CYP2C9 and CYP2C19, the star 
nomenclature was used to describe some alleles of a gene and additional alleles of the gene 
were named by the predicted amino acid change (Table 1).
The assays used in this study varied in many ways. Without exception, no two assays that 
examined a particular gene were designed to detect the same set of haplotypes (Table 1). In 
addition, some assays used different combinations of variants to define the haplotypes that 
the assay detected, which ultimately can lead to discrepancies in reported star allele 
genotypes between platforms. For example in CYP2D6, c.2850C>T and c.4180G>C, which 
are the defining variants for *2 (c.2850C>T, c.4180G>C), also occur in various other 
haplotypes such as *17 (c. 1023C>T, c.2850C>T, c.4180G>C), and *21 (c.2573_2574insC, 
c.2850C>T, c.4180G>C). *2 is a functional allele, while *17 has decreased function and *21 
is non-functional. Determining the presence of duplications as well as multiplications in 
CYP2D6 is also important25 as CYP2D6*2XN (c.2850C>T, c.4180G>C, >2) is an increased 
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function allele. Figure 1 shows how differences in the design of CYP2D6 assays (e.g., 
variable inclusion of certain variants and or copy number detection) may impact 
interpretation of alleles. Additionally, we did not assign phase to the various variants during 
this study, which may have implications in result interpretation and therefore deserves 
further review.
This study highlights how the common PGx nomenclature system and variable assay 
designs add to the complexity of analyzing and reporting results from pharmacogenetic 
assays, especially when trying to compare data from the same sample analyzed on different 
genotyping platforms. These discrepancies could hinder patient care and adoption of 
pharmacogenetic assays in clinical practice. For example, physicians may have difficulty 
understanding laboratory reports when results from different laboratories and in the 
literature are described using a variety of nomenclature systems. Such inconsistencies might 
lead to mistakes in treatment and hinder adoption and use of pharmacogenetic tests. 
Similarly, regulatory agencies, proficiency testing programs and test developers require 
standardized nomenclature so that results can be compared between platforms and also with 
previous scientific literature. Lack of a consistent nomenclature could stifle regulatory 
clearance or approval of new assays and add undue confusion to analysis of proficiency 
testing surveys. Finally, standardization of nomenclature is critical for the accurate 
accumulation of data in clinical databases, such as ClinVar http://www.ncbi.nlm.nih.gov/
clinvar/ last accessed 3/30/2015) and PharmGKB. Without standardization, multiple 
observations of the same genotype could not be related to each other, and incorrect 
relationships between genotype and phenotype may be inferred.
To address these nomenclature issues, the GeT-RM program formed an international 
workgroup to review current pharmacogenetic nomenclature practices and develop a system 
based on the HGVS nomenclature to describe pharmacogenetic haplotypes and facilitate 
translation between different nomenclature systems. Workgroup participants include many 
significant stakeholders in pharmacogenetics [PharmGKB, the Pharmacogenetics Research 
Network (PGRN), and the Clinical Pharmacogenetics Implementation Consortium (CPIC)], 
regulatory agencies [the Food and Drug Administration (FDA)], Laboratory accrediting 
organizations [the College of American Pathologists (CAP)], nomenclature committees [The 
Human Genome Organisation (HUGO), and the Human Genome Variation Society 
(HGVS)], others that are responsible for a number of gene/mutation databases [the National 
Center for Biotechnology Information (NCBI), ClinVar, TPMT, CYP450 databases], 
pharmacogenetic assay developers, and clinical and research laboratories. The group has 
developed a system to standardize the way pharmacogenetic haplotypes are described and 
reported, as well as recommendations for ways to standardize pharmacogenetic assays. We 
are also developing graphical examples to represent pharmacogenetic haplotypes that would 
allow easy conversion between different nomenclatures.
In conclusion, this characterized set of 137 genomic DNA RMs are available for use in 
research, clinical test development, quality assurance and control, and proficiency testing to 
help to ensure the accuracy of clinical pharmacogenetic testing. These pharmacogenetic 
RMs, as well as other materials developed by GeT-RM, are publically available from the 
NIGMS and NHGRI repositories at the Coriell Cell Repositories (https://catalog.coriell.org/, 
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last accessed September 12, 2014). Information on this and other RM characterization 
projects is available at the GeT-RM website.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Assay design can cause inconsistent allele calls and interpretation
A CYP2D6 assay that only detects c.2850C>T (rs16947) and c.4180G>C (rs1135840) 
without copy number, cannot distinguish between *2 (c.2850C>T, c.4180G>C), *17 (c.
1023C>T [rs28371706], c.2850C>T, c.4180G>C), *21 (c.2573_2574insT [rs72549352], c.
2850C>T, c.4180G>C), or *2XN (c.2850C>T, c.4180G>C, XN), which have different 
predicted phenotypes. EM: Extensive metabolizer, IM: Intermediate metabolizer, UM: 
Ultrarapid metabolizer.
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